The drug, sotatercept of Acceleron Pharma, touches the phase 2 mark
Acceleron Pharma, a clinical-stage biopharmaceutical company based in Boston, Massachusetts with a primary aim on the development of medicines that regulate the transforming growth factor-beta (TGF-β) superfamily of proteins that play significant roles.
The biotech has observed success in phase 2 for sotatercept drug for Pulmonary Arterial Hypertension. The disease is a rare disorder in which patients have high blood pressure in the arteries of the lungs. The examination of the drug involved around 106 patients to receive either placebo or one of two dose levels of sotatercept in an injection ju...
